Bicara Therapeutics Past Earnings Performance
Past criteria checks 0/6
Bicara Therapeutics's earnings have been declining at an average annual rate of -44.6%, while the Biotechs industry saw earnings growing at 19% annually.
Key information
-44.6%
Earnings growth rate
-5.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -33.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Bicara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -65 | 13 | 45 |
| 31 Mar 24 | 0 | -58 | 11 | 38 |
| 31 Dec 23 | 0 | -52 | 9 | 31 |
Quality Earnings: BCAX is currently unprofitable.
Growing Profit Margin: BCAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if BCAX's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare BCAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).
Return on Equity
High ROE: BCAX has a negative Return on Equity (-33.68%), as it is currently unprofitable.